• Features of maintenance of asthma control in adolescents in the period of the clinical well-doing 
To content

Features of maintenance of asthma control in adolescents in the period of the clinical well-doing 

SOVREMENNAYA PEDIATRIYA.2015.7(71):76-79; doi 10.15574/SP.2015.71.76 
 

Features of maintenance of asthma control in adolescents in the period of the clinical well-doing 
 

Koloskova O. K., Shahova O. O.

HSEIU «Bukovina State Medical University», Chernivtsi, Ukraine 
 

Goal. To investigate the effectiveness of asthma control and to determine risk of its loss in adolescents in clinical remission period, depending on the severity of the disease, and to make a cluster model of the control of this disease of childhood. 
 

Materials and methods. The probability of keeping control of the disease and the risk of its loss in the period of remission for the varying severity of asthma was analyzed in 43 adolescents suffering from asthma in a state of clinical well-being. Two asthma control questionnaires were used: ACT-test (astma control test) — which allowed in the presence of 25 points to verify the complete asthma control, 20–24 — partial, less than 20 points — the lack of control over the disease; and GINA-test that reflected in adolescents the same level of control in the presence of the 6 points, 7–9 and 10 points or more respectively. 
 

Results. It was shown that adolescents with moderate severity of the disease had more common tendency to achieve full control over the disease, and rarely — lost control during the survey using ACT-test. While the use of GINA-test to assess the level of control made the contradictory results that were more dependent on unaccounted factors than on the severity of asthma before the start of the control treatment. Cluster of adolescents with insufficient control of symptoms was characterized by the increased bronchial hyperresponsiveness and markers of bronchial inflammation. 
 

Conclusion. In the period of clinical well-being risk of loss of control of the disease (according to the ACT-test) increased three times in adolescents who suffer from severe persistent asthma compared with their peers with medium-severe form of the disease. In case of the presence of the signs of subclinical inflammation in the bronchi and their hyperresponsiveness in adolescents with severe asthma but with the signs of the clinical well-being, doctor should consider the appointment of the base treatment. 
 

Key words: bronchial asthma, adolescents, bronchial lability, hyperreactivity, hyperresponsiveness. 
 

REFERENCES

1. Огородникова ЛМ, Шахова ИВ, Еврокимова ТА и др. 2009. Анализ приверженности АСТ в процессе ведения больных в первом звене здравоохранения. Педиатрическая фармакология. 6;2: 36—39.

2. Ненашева НМ. 2008. Контроль бронхиальной астмы у подростков. Педиатрическая фармакология. 5;3: 98—103.

3. Огородова АМ, Петровский ФИ. 2008. Стремление к контролю астмы: новые данные исследование GOAL. Пульмонология. 2: 105—110.

4. Сажин СІ. 2011. Ефективність альтернативних режимів зменшення обсягу контрольованої терапії бронхіальної астми у дітей шкільного віку. Дис канд.мед.наук. 14.01.10. Чернівці: 160.

5. Яковлева ОА, Жамба АО. 2008. Бронхиальная астма: уровень контроля симптомов. Ліки України. 4: 118—120.

6. Taylor DR, Bateman ED, Boulet LP et al. 2008. A new perspective on concept of asthma severity and control. Eur Respir J. 32: 545—554. http://dx.doi.org/10.1183/09031936.00155307; PMid:18757695

7. Boulet LPh, Chanez P. 2015. Clinically Relevant Outcome Measures for New Therapies of Asthma Using Pharmaceutical and Biologic Agents. Allergy Clin Immunol. 15(3): 213—219. http://dx.doi.org/10.1097/aci.0000000000000165

8. Cowan DC, Cowan JO, Palmay R et al. 2010. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 65: 384—390. http://dx.doi.org/10.1136/thx.2009.126722; PMid:19996343

9. Hanania NA. 2009. Asthma control: a new perspective on the management of asthma. Curr Opin Pulmonary Med. 15: 1—3. http://dx.doi.org/10.1097/MCP.0b013e32831e9701; PMid:19077698

10. Hanania NA, Noonan M, Korenblat JCPh et al. 2015. Lebrikizumab in Moderate-to-Severe Asthma. Thorax. 70(8): 748—756. http://dx.doi.org/10.1136/thoraxjnl-2014-206719; PMid:26001563 PMCid:PMC4515999

11. Montuschi P, Pagliari G, Fuso L. 2009. Pharmacotherapy of Asthma: regular treatment or on demand? Ther Adv Respir Dis. 3: 175—191. http://dx.doi.org/10.1177/1753465809343711; PMid:19671618

12. Shen J, Jonson M, Hays RD. 2011. Asthma outcome measures. Exp Rev Pharm Outcomes Res. 11;4: 447—453. http://dx.doi.org/10.1586/erp.11.48